Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in retinal amacrine cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 305 | 0.76 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4115
Sealed predictions
- NPAS4 in dopamine neurons, braak-0.43 (p 0.251) → -0.22 (p 0.567)receipt 4120
Swarm cases
receipt 4120: NPAS4 in dopamine neurons, braak
- power
- full sample -0.30 (p 0.232, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.167, n 18). could be the mix.
- skeptic
- leave-one-out range -0.46 to -0.23, sign flips 0; without severely affected donors -0.30 (p 0.232, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NPAS4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts